Christopher G. Bunick, MD, PhD

Discussing the Most Exciting Events at 2025 RAD Conference, with Christopher Bunick, MD, PhD

2025 Revolutionizing Atopic Dermatitis (RAD) Meeting

 is scheduled to take place from June 6 - 7 in Nashville, Tennessee, with attendees being given a chance to attend informative sessions, learn about new data, and network with one another.

In a recent interview, Christopher G. Bunick, MD, PhD, associate professor of dermatology at the Yale University School of Medicine, spoke about his own presentation at the RAD conference as well as what he is most looking forward to during the meeting.

“What am I most excited about?” Bunick said. “The answer is, I'm excited about learning new content. I'm excited about learning the cutting-edge new trials and new innovations. I think it's really important to know what's happening in the field so that I can best advise my patients. So I'm very excited about learning. You know, I always joke with people that I never need coffee. I just need science. That's my most exciting part of going to RAD is learning more science so I can better help my patients.”

Bunick further highlighted that interactions with colleagues in the dermatology space is 1 of the most enjoyable parts of attending conferences like RAD.

“One of the greatest joys of our profession, particularly dermatology, is that we have great colleagues,” Bunick explained. “To be able to interact with them and learn from them is a tremendous resource for collegiality and learning. Lastly, I'm looking forward to getting back to my home state of Tennessee, spending some time in Nashville.”

To sign up for the 2025 RAD conference, check out 

. For additional information from Bunick, view the full interview clip above.

The quotes contained in this summary were edited for the purposes of clarity.

Videos

In this interview, Christopher Bunick, MD, PhD, speaks on the elements of the RAD 2025 conference that he is most anticipating.


Key Takeaways on the Role of Oral JAK Inhibitors in Atopic Dermatitis Management

Video content above is prompted by the following:

What are some key takeaways or advice for other dermatologists treating patients with atopic dermatitis with JAK inhibitors?

Experts discuss key takeaways for dermatologists managing atopic dermatitis with JAK inhibitors, emphasizing the importance of individualized treatment plans, monitoring for safety and efficacy, and balancing the benefits of JAK inhibitors with potential risks, especially in long-term use.

Oral JAK Inhibitor Dose Escalation in Atopic Dermatitis Treatment

With JAK inhibitor therapy, the dose can be increased if needed based on clinical judgment. How do you decide when a patient should increase the dose of their JAK inhibitor?

How often do you increase to the higher dose of JAK inhibitors in practice?

Experts discuss how clinical judgment guides the decision to increase the dose of a JAK inhibitor, considering factors like patient response and symptom severity, and how often dose escalation is implemented in practice based on individual patient needs.

Addressing Treatment Response and Switching Among Systemic Therapies in Atopic Dermatitis

Several studies have shown that patients who have not responded to biologic therapy can achieve improved results when switching to a JAK inhibitor. How do these data impact your clinical practice and your threshold for switching systemic therapies for patients?

Experts discuss how data from studies like JADE EXTEND, Heads Up Extension, and LEVEL UP, showing improved outcomes with JAK inhibitors in patients who failed biologic therapy, influence their clinical practice and decision-making when considering switching systemic therapies for patients with atopic dermatitis.

Christopher G. Bunick, MD, PhD

Articles